Vital Therapies reported $-20808000 in Pre-Tax Profit for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Biomarin Pharmaceutical BMRN:US $ 26.19M 92.76M
Dynavax Technologies DVAX:US $ 32.86M 67.73M
Enanta Pharmaceuticals ENTA:US $ -33.59M 3.44M
Epizyme EPZM:US $ -55.47M 4.84M
Insmed INSM:US $ -94236000 18.78M
Intercept Pharmaceuticals ICPT:US $ -17.28M 19M
Mirati Therapeutics MRTX:US $ -188.39M 11.23M
Omeros OMER:US $ -39494000 7.82M
Orasure Technologies OSUR:US $ -16.03M 7.1M
Regulus Therapeutics RGLS:US $ -6.72M 0.42M
Revance Therapeutics RVNC:US $ -64.34M 1.24M
Ultragenyx Pharmaceutical RARE:US $ -151.76M 29.32M
United Therapeutics UTHR:US $ 308.7M 168.2M
Vital Therapies VTL:US $ -20.81M 0.38M
Xoma XOMA:US $ -2.28M 32.22M